Published in N Engl J Med on December 03, 1992
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ (2009) 7.64
Estimates of optimal vitamin D status. Osteoporos Int (2005) 7.13
Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ (2015) 4.29
Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ (2005) 4.04
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ (2009) 2.90
Effect of calcium supplementation on hip fractures. Osteoporos Int (2008) 2.79
Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues? Osteoporos Int (2014) 2.74
Vitamin D insufficiency in a population of healthy western Canadians. CMAJ (2002) 2.73
Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ (2010) 2.67
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Calcium intake and risk of fracture: systematic review. BMJ (2015) 2.60
Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int (2007) 2.56
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys (2007) 2.39
Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int (2010) 2.35
Current and potential future drug treatments for osteoporosis. Ann Rheum Dis (1996) 2.21
How many, how old, how soon? BMJ (1999) 2.14
A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med (2005) 2.10
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Vitamin D status and its relationship with bone mineral density in healthy Asian Indians. Osteoporos Int (2003) 2.04
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J Clin Endocrinol Metab (2007) 1.96
Vitamin D - effects on skeletal and extraskeletal health and the need for supplementation. Nutrients (2013) 1.81
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Benefit-risk assessment of vitamin D supplementation. Osteoporos Int (2009) 1.70
Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res (2009) 1.66
Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab (2008) 1.65
Assessment and management of nutrition in older people and its importance to health. Clin Interv Aging (2010) 1.61
Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int (2015) 1.60
Managing osteoporosis in older people with fractures. BMJ (1999) 1.60
Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc (2010) 1.60
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ (2010) 1.59
Preventing fractures in elderly people. BMJ (2003) 1.57
Prevalence of vitamin D insufficiency in postmenopausal south Indian women. Osteoporos Int (2004) 1.55
Calcium and vitamin D: skeletal and extraskeletal health. Curr Rheumatol Rep (2008) 1.54
Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol (2009) 1.51
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women. Osteoporos Int (2004) 1.51
Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.50
Validation of a 4-item score predicting hip fracture and mortality risk among elderly women. Ann Fam Med (2007) 1.48
Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int (2004) 1.48
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ (2010) 1.45
Vitamin D status among patients with hip fracture and elderly control subjects in Yekaterinburg, Russia. Osteoporos Int (2005) 1.42
Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int (1997) 1.42
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int (2004) 1.39
Bone mineral density measurements: are they worth while? J R Soc Med (1996) 1.39
Dose response to vitamin D supplementation among postmenopausal African American women. Am J Clin Nutr (2007) 1.39
Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ (1996) 1.38
Vitamin D levels in healthy men in eastern Saudi Arabia. Ann Saudi Med (2009) 1.38
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat (2009) 1.37
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int (2005) 1.35
Vitamin D in health and disease: current perspectives. Nutr J (2010) 1.31
Musculoskeletal pain in female asylum seekers and hypovitaminosis D3. BMJ (2004) 1.30
Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults. J Am Coll Nutr (2008) 1.29
Optimal management of sarcopenia. Clin Interv Aging (2010) 1.29
Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures. Osteoporos Int (2003) 1.28
Vitamin D status and calcium metabolism in adolescent black and white girls on a range of controlled calcium intakes. J Clin Endocrinol Metab (2008) 1.26
Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int (2006) 1.25
Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older. Osteoporos Int (2006) 1.24
Rheumatology: 15. Osteoporosis. CMAJ (2001) 1.20
Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut (1995) 1.20
Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int (2005) 1.18
Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol (2008) 1.17
Vitamin D status and its relation to muscle mass and muscle fat in young women. J Clin Endocrinol Metab (2010) 1.17
Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int (2004) 1.15
Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff. Osteoporos Int (2003) 1.15
Changes in drug treatment in the elderly between 1971 and 2000. Eur J Clin Pharmacol (2003) 1.15
Osteoporosis management in long-term care. Survey of Ontario physicians. Can Fam Physician (2000) 1.14
Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects. J Neuroeng Rehabil (2010) 1.14
Effect of seasonality and weather on fracture risk in individuals 65 years and older. Osteoporos Int (2007) 1.13
Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study. J Clin Endocrinol Metab (2011) 1.12
Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr (2008) 1.12
Multifactorial analysis of risk factors for reduced bone mineral density among postmenopausal women. Arch Med Sci (2012) 1.11
Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int (2007) 1.09
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int (2004) 1.09
Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int (2003) 1.09
Milk, dietary calcium, and bone fractures in women: a 12-year prospective study. Am J Public Health (1997) 1.08
Determinants of vitamin D status in older women living in a subtropical climate. Osteoporos Int (2005) 1.08
How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int (2006) 1.08
Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporos Int (2010) 1.07
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol (2004) 1.07
Prevention of falls in older people with dementia. J Neural Transm (Vienna) (2007) 1.07
Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications. Osteoporos Int (2007) 1.06
Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int (2007) 1.06
Vitamin D insufficiency: no recommended dietary allowance exists for this nutrient. CMAJ (2002) 1.05
Bisphosphonates in osteoporosis. Eur Spine J (2003) 1.05
Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ (2005) 1.05
Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J Gen Intern Med (2002) 1.04
Hip fracture patients in India have vitamin D deficiency and secondary hyperparathyroidism. Osteoporos Int (2012) 1.03
Meta-analysis of long-term vitamin D supplementation on overall mortality. PLoS One (2013) 1.03
The biology and pathology of vitamin D control in bone. J Cell Biochem (2010) 1.03
Subsequent fracture in nursing home residents with a hip fracture: a competing risks approach. J Am Geriatr Soc (2008) 1.01
25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol (2012) 1.01
Osteoporosis prevention, screening, and treatment: a review. J Womens Health (Larchmt) (2014) 1.01
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int (1997) 5.82
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Dietary supplementation in elderly patients with fractured neck of the femur. Lancet (1990) 4.47
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Do we need to change the WHO definition of osteoporosis? Osteoporos Int (2000) 3.35
Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet (1996) 3.18
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet (1996) 2.83
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int (2002) 2.82
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res (2000) 2.24
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
The role of collagen in bone strength. Osteoporos Int (2005) 2.19
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis (2001) 2.18
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev (2006) 2.08
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry (1992) 1.89
Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum (2000) 1.85
Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res (1978) 1.83
Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab (1990) 1.83
Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France. Eur Respir J (1996) 1.83
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone (1996) 1.80
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res (1998) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab (1988) 1.71
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet (1994) 1.71
How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int (1998) 1.70
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner (1990) 1.62
Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res (2001) 1.62
The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol (1998) 1.59
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int (1993) 1.58
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone (2003) 1.54
The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone (2004) 1.54
Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab (1996) 1.53
Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet (1988) 1.50
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Prevention and treatment of osteoporosis. Aging (Milano) (1995) 1.50
Fluoride and vertebral fractures. Lancet (1990) 1.48
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res (1996) 1.48
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med (1995) 1.48
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) J Clin Endocrinol Metab (1997) 1.48
Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br J Rheumatol (1989) 1.48
Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med (1999) 1.48
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr (1987) 1.46
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res (1997) 1.42
Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res (1997) 1.42
Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone (1999) 1.41
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer (1994) 1.41
Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int (2000) 1.41
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
[Dyspepsia--can we follow dogmatic guidelines in a nuanced reality? Individual management of patients with dyspepsia with risk of stomach ulcer]. Lakartidningen (1999) 1.39
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res (1997) 1.39
Dual energy X-ray absorptiometry in patients with lower limb reflex sympathetic dystrophy syndrome. J Rheumatol (1996) 1.38